The Federal Bureau of Prisons (BOP) has suspended an arrangement with a Florida-based start-up to sell nicotine pouches in federal commissaries after a whistleblower complaint and inquiries regarding the product's regulatory status. The suspension, ordered on Sept. 3, 2026, halted the procurement and sale of "mindSHFT" brand pouches, which had been authorized for sale to inmates in July. The pouches are not authorized for marketing by the Food and Drug Administration (FDA).
The BOP initiated the sale of nicotine pouches to combat the trafficking of contraband tobacco and nicotine products within its institutions. Internal memos indicate the agency sought to generate revenue for its Trust Fund, which was reported by BOP Director William Marshall in May to be operating at a $23 million annual loss. Although a 2014 rule prohibits tobacco-related products in federal prisons, the BOP determined this did not apply to nicotine pouches, which were not commercially available at the time the rule was drafted.
Details of the procurement show that SHFT Enterprise Holdings LLC was incorporated in Florida in May, one week after the BOP issued a nationwide request for information (RFI) for "FDA-authorized nicotine pouch products." The BOP did not issue a formal request for proposals or sign a contract with the company. However, Trust Fund Chief Adam Morrow informed prisons on July 21 that SHFT was the approved vendor. Internal records show the agency purchased the tins for $6.99 each and sold them to inmates for $9.10, with some individual prison orders ranging from $3,000 to $28,000.
The scale of the financial arrangement involved recommended orders of three tins per inmate across 118 institutions. At a resale price of $9.10 per tin, a full initial stocking for the entire federal population would have represented approximately $4.1 million in inmate expenditures. A correctional official expressed security concerns regarding the introduction of nicotine products into facilities where officers are prohibited from smoking. The BOP stated the vendor had claimed the products were sold legally and had obtained FDA approval, despite FDA records showing only two other major tobacco companies held such authorizations at the time.
What happens next: The BOP has stated that a legal review of existing inventory is ongoing following consultations with the FDA. While a source familiar with the procurement reported no illnesses or adverse effects have been documented, the agency has not set a date for when, or if, nicotine pouch sales will resume. The Justice Department's inspector general and Attorney General Todd Blanche have been notified of the matter via a whistleblower complaint, which may lead to further investigation into the procurement process and the business ties of SHFT Enterprise Holdings LLC. As of early 2025, the FDA had authorized 20 ZYN nicotine pouch products, which are separate from the mindSHFT brand sold to the BOP.